FDA Approves Brepocitinib, First Oral Drug for Dermatomyositis in Adults

The FDA approved brepocitinib (Lisraya) as the first oral treatment for adult dermatomyositis, supported by positive phase 3 trial results showing significant clinical improvements and steroid-sparing benefits. The drug received orphan and priority review designations, marking a regulatory milestone for this rare autoimmune disease with few treatment options.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it.